

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4850676

| | |
|---|---|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| | |
| Name | Execution Date |
| ALBERTO ORTEGA MUÑOZ | 07/08/2016 |
| MATTHEW COLIN THOR FYFE | 07/11/2016 |
| MARC MARTINELL PEDEMONTE | 07/11/2016 |
| MARIA DE LOS ÁNGELES ESTIARTE MARTINEZ | 07/11/2016 |
| NURIA VALLS VIDAL | 07/14/2016 |
| GUIDO KURZ | 07/11/2016 |
| RECEIVING PARTY DATA | |
| Name: | ORYZON GENOMICS S.A. |
| Street Address: | C/SANT FERRAN 74 |
| Internal Address: | CORNELLA DE LLOBREGAT |
| City: | BARCELONA |
| State/Country: | SPAIN |
| Postal Code: | 08940 |
| PROPERTY NUMBERS Total: 1 | |
| | |
| Property Type | Number |
| Application Number: | 15271772 |
| CORRESPONDENCE DATA | |
| Fax Number: | (202)408-4400 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | 202-408-4000 |
| Email: | pam.gebhardtsbauer@finnegan.com |
| Correspondent Name: | FINNEGAN, HENDERSON, FARABOW, GARRETT & |
| Address Line 1: | 901 NEW YORK AVENUE, NW |
| Address Line 4: | WASHINGTON, D.C. 20001-4413 |
| ATTORNEY DOCKET NUMBER: | 12064.0019-01000 |
| NAME OF SUBMITTER: | PAMELA A. GEBHARDTSBAUER |
| SIGNATURE: | /Pamela A. Gebhardtsbauer/ |
| DATE SIGNED: | 03/05/2018 |

Total Attachments: 14

source=Assignment#page1.tif
source=Assignment#page2.tif
source=Assignment#page3.tif
source=Assignment#page4.tif
source=Assignment#page5.tif
source=Assignment#page6.tif
source=Assignment#page7.tif
source=Assignment#page8.tif
source=Assignment#page9.tif
source=Assignment#page10.tif
source=Assignment#page11.tif
source=Assignment#page12.tif
source=Assignment#page13.tif
source=Assignment#page14.tif

ASSIGNMENT

WHEREAS I/We, the below-named inventor(s) (hereinafter referred to as Assignor(s)), of an invention entitled:

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

as disclosed and claimed in EP Application No. 11382325.6, filed October 20, 2011, EP Application No. 11382331.4, filed October 27, 2011, United States Provisional Patent Application No. 61/558,367, filed November 10, 2011, United States Provisional Patent Application No. 61/558,365, filed November 10, 2011, United States Application No. 14/352,711, filed April 18, 2014 (Confirmation No. 2828) and/or PCT International Application No. PCT/EP2012/070898, filed October 22, 2012 and;

WHEREAS, Oryzon Genomics S.A., a corporation of Spain whose post office address is C/Sant Ferran 74, 08940 Cornellà de Llobregat, Barcelona, Spain (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I/We, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my/our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and I/We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY covenant that I/We have the full right to convey the interest assigned by this Assignment, and I/We have not executed and will not execute any agreement in conflict with this Assignment;

AND, I/WE HEREBY further covenant and agree that I/We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

AND, I/WE HEREBY authorize and request the attorneys empowered in the Power of Attorney in this application, to insert the filing date and application number of the above-referenced application(s) when known.


IN TESTIMONY WHEREOF, I/We have hereunto set our hands.

Name: Alberto Ortega Muñoz

Address: [Address] C/O ORYZON GENOMICS, S.A.
CALLE SANT FERRAN 74, 08940 CORNELLA DE LLOBREGAT, SPAIN

By:

Date: JULY 8th, 2016



Name: Matthew Colin Thor Fyfe
Address: [Address]
By: _____
Date: _____


Name: Marc Martineil Pedemonte
Address: [Address]
By: _____
Date: _____

Name: Maria de los Angeles Estariz Martínez
Address: [Address]
By: _____
Date: _____

Name: Nuria Valls Vidal
Address: [Address]
By: _____
Date: _____

Name: Guido Kurz
Address: [Address]
By: _____
Date: _____

Name: Julio Cesar Castro Palomino Laria
Address: [Address]
By: _____
Date: _____

Assignee Name: Orizon Genomics S.A.
Signature: 
Printed Name: CARLOS RUCINA ARBOL
Corporate Title: C.E.O.
Date: 20 - JULY - 2016

ASSIGNMENT

WHEREAS I/We, the below-named inventor(s) (hereinafter referred to as Assignor(s)), of an invention entitled:

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

as disclosed and claimed in EP Application No. 11382325.6, filed October 20, 2011, EP Application No. 11382331.4, filed October 27, 2011, United States Provisional Patent Application No. 61/558,367, filed November 10, 2011, United States Provisional Patent Application No. 61/558,365, filed November 10, 2011, United States Application No. 14/352,711, filed April 18, 2014 (Confirmation No. 2828) and/or PCT International Application No. PCT/EP2012/070898, filed October 22, 2012 and;

WHEREAS, Oryzon Genomics S.A., a corporation of Spain whose post office address is C/Sant Ferran 74, 08940 Cornellà de Llobregat, Barcelona, Spain (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I/We, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my/our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and I/We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY covenant that I/We have the full right to convey the interest assigned by this Assignment, and I/We have not executed and will not execute any agreement in conflict with this Assignment;

AND, I/WE HEREBY further covenant and agree that I/We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

AND, I/WE HEREBY authorize and request the attorneys empowered in the Power of Attorney in this application, to insert the filing date and application number of the above-referenced application(s) when known.

IN TESTIMONY WHEREOF, I/We have hereunto set our hands.

Name: Alberto Ortega Muñoz
Address: [Address]
By: _____
Date: _____

Name: Matthew Colin Thor Fyfe
Address: [Address] CHIFFING NOTON
UNITED KINGDOM
By: Matthew Fyfe
Date: 11 JULY 2016

Matthew Fyfe


Name: Marc Martinell Pedemonte
Address: [Address]
By:
Date:

Name: Maria de los Angeles Estiarte Martinez
Address: [Address]
By:
Date:

Name: Nuria Valls Vidal
Address: [Address]
By:
Date:

Name: Guido Kurz
Address: [Address]
By:
Date:

Name: Julio Cesar Castro Palomino Laria
Address: [Address]
By:
Date:

Assignee Name: Oryzon Genomics S.A.
Signature: 
Printed Name: CARLOS BUSTA ALZOL
Corporate Title: CEO
Date: 20-JULY-2016

ASSIGNMENT

WHEREAS I/We, the below-named inventor(s) (hereinafter referred to as Assignor(s)), of an invention entitled:

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

as disclosed and claimed in EP Application No. 11382325.6, filed October 20, 2011, EP Application No. 11382331.4, filed October 27, 2011, United States Provisional Patent Application No. 61/558,367, filed November 10, 2011, United States Provisional Patent Application No. 61/558,365, filed November 10, 2011, United States Application No. 14/352,711, filed April 18, 2014 (Confirmation No. 2828) and/or PCT International Application No. PCT/EP2012/070898, filed October 22, 2012 and;

WHEREAS, Oryzon Genomics S.A., a corporation of Spain whose post office address is C/Sant Ferran 74, 08940 Cornellà de Llobregat, Barcelona, Spain (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I/We, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my/our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and I/We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY covenant that I/We have the full right to convey the interest assigned by this Assignment, and I/We have not executed and will not execute any agreement in conflict with this Assignment;

AND, I/WE HEREBY further covenant and agree that I/We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

AND, I/WE HEREBY authorize and request the attorneys empowered in the Power of Attorney in this application, to insert the filing date and application number of the above-referenced application(s) when known.

IN TESTIMONY WHEREOF, I/We have hereunto set our hands.

Name: Alberto Ortega Muñoz
Address: [Address]
By: _____
Date: _____

Name: Matthew Colin Thor Fyfe
Address: [Address]
By: _____
Date: _____

Name: Marc Martinell Pedemonte
Address: [Address] N. MICHAEL 2° 1 2° 2
94305 2007 (PE DE MADRE 81000)
By: _____
Date: [Signature] July 11th 2016

Name: María de los Ángeles Estiarte Martínez
Address: [Address]
By: _____
Date: _____

Name: Nuria Vallis Vidal
Address: [Address]
By: _____
Date: _____

Name: Guido Kurz
Address: [Address]
By: _____
Date: _____

Name: Julio Cesar Castro Palomino Laría
Address: [Address]
By: _____
Date: _____

Assignee Name: Oryzon Genomics S.A.
Signature: [Signature]
Printed Name: CATALINA BUCON ARRIAGA
Corporate Title: S.E.O
Date: 27 July 2016

ASSIGNMENT

WHEREAS I/We, the below-named inventor(s) (hereinafter referred to as Assignor(s)), of an invention entitled:

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

as disclosed and claimed in EP Application No. 11382325.6, filed October 20, 2011, EP Application No. 11382331.4, filed October 27, 2011, United States Provisional Patent Application No. 61/558,367, filed November 10, 2011, United States Provisional Patent Application No. 61/558,365, filed November 10, 2011, United States Application No. 14/352,711, filed April 18, 2014 (Confirmation No. 2828) and/or PCT International Application No. PCT/EP2012/070898, filed October 22, 2012 and;

WHEREAS, Oryzon Genomics S.A., a corporation of Spain whose post office address is C/Sant Ferran 74, 08940 Cornellà de Llobregat, Barcelona, Spain (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I/We, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my/our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and I/We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY covenant that I/We have the full right to convey the interest assigned by this Assignment, and I/We have not executed and will not execute any agreement in conflict with this Assignment;

AND, I/WE HEREBY further covenant and agree that I/We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.


AND, I/WE HEREBY authorize and request the attorneys empowered in the Power of Attorney in this application, to insert the filing date and application number of the above-referenced application(s) when known.

IN TESTIMONY WHEREOF, I/We have hereunto set our hands.

Name: Alberto Ortega Muñoz
Address: [Address]
By: _____
Date: _____

Name: Matthew Colin Thor Fyfe
Address: [Address]
By: _____
Date: _____

Name: Marc Martinell Pedemonte
Address: [Address]
By: _____
Date: _____

Name: María de los Angeles Estiarte Martínez
Address: [Address] San Francisco, CA
By: 
Date: 11 Jul 2016

Name: Nuria Valls Vidal
Address: [Address]
By: _____
Date: _____

Name: Guido Kurz
Address: [Address]
By: _____
Date: _____

Name: Julio Cesar Castro Palomino Laria
Address: [Address]
By: _____
Date: _____

Assignee Name: Oryzon Genomics S.A.

Signature: 

Printed Name: CARLOS MAZA ARJOLA

Corporate Title: C.E.O.

Date: 25-Jul-2016

ASSIGNMENT

WHEREAS I/We, the below-named inventor(s) (hereinafter referred to as Assignor(s)), of an invention entitled:

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

as disclosed and claimed in EP Application No. 11382325.6, filed October 20, 2011, EP Application No. 11382331.4, filed October 27, 2011, United States Provisional Patent Application No. 81/558,367, filed November 10, 2011, United States Provisional Patent Application No. 61/558,365, filed November 10, 2011, United States Application No. 14/352,711, filed April 18, 2014 (Confirmation No. 2828) and/or PCT International Application No. PCT/EP2012/070898, filed October 22, 2012 and;

WHEREAS, Oryzon Genomics S.A., a corporation of Spain whose post office address is C/Sant Ferran 74, 08940 Cornellà de Llobregat, Barcelona, Spain (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I/We, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my/our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and I/We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY covenant that I/We have the full right to convey the interest assigned by this Assignment, and I/We have not executed and will not execute any agreement in conflict with this Assignment;

AND, I/WE HEREBY further covenant and agree that I/We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

AND, I/WE HEREBY authorize and request the attorneys empowered in the Power of Attorney in this application, to insert the filing date and application number of the above-referenced application(s) when known.

IN TESTIMONY WHEREOF, I/We have hereunto set our hands.

Name: Alberto Ortega Muñoz
Address: [Address]

By: _____
Date: _____

Name: Matthew Colin Thor Fyfe
Address: [Address]
By: _____
Date: _____


Name: Marc Martinelli Pademonte
Address: [Address]
By: _____
Date: _____

Name: María de los Ángeles Estiarte Martínez
Address: [Address]
By: _____
Date: _____

Name: Nuria Valls Vidal
Address: [Address] C/ Valls 18, 1º 08018
Barcelona, Spain
By: _____
Date: July 19, 2016

Name: Guido Kurz
Address: [Address]
By: _____
Date: _____

Name: Julio Cesar Castro Palomino Laría
Address: [Address]
By: _____
Date: _____

Assignee Name: Oryzon Genomics S.A.
Signature: 
Printed Name: CARLOS BUETA ARIZA
Corporate Title: C.E.O.
Date: 20 July 2016

ASSIGNMENT

WHEREAS I/We, the below-named inventor(s) (hereinafter referred to as Assignor(s)), of an invention entitled:

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

as disclosed and claimed in EP Application No. 11382325.6, filed October 20, 2011, EP Application No. 11382331.4, filed October 27, 2011, United States Provisional Patent Application No. 61/558,367, filed November 10, 2011, United States Provisional Patent Application No. 61/558,365, filed November 10, 2011, United States Application No. 14/352,711, filed April 18, 2014 (Confirmation No. 2828) and/or PCT International Application No. PCT/EP2012/070898, filed October 22, 2012 and;

WHEREAS, Oryzon Genomics S.A., a corporation of Spain whose post office address is C/Sant Ferran 74, 08940 Cornellà de Llobregat, Barcelona, Spain (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I/We, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my/our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and I/We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY covenant that I/We have the full right to convey the interest assigned by this Assignment, and I/We have not executed and will not execute any agreement in conflict with this Assignment;

AND, I/WE HEREBY further covenant and agree that I/We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

AND, I/WE HEREBY authorize and request the attorneys empowered in the Power of Attorney in this application, to insert the filing date and application number of the above-referenced application(s) when known.

IN TESTIMONY WHEREOF, I/We have hereunto set our hands.

Name: Alberto Ortega Muñoz
Address: [Address]
By: _____
Date: _____

Name: Matthew Colin Thor Fyfe
Address: [Address]

By: _____
Date: _____

Name: Marc Martinell Pedemonte
Address: [Address]

By: _____
Date: _____

Name: Maria de los Angeles Estiarte Martínez
Address: [Address]

By: _____
Date: _____

Name: Nuria Valls Vidal
Address: [Address]

By: _____
Date: _____

Name: Guido Kurz
Address: [Address]

By: LLUIS DOMENECH
INVENTOR 6
ORISU EQUILIBRES DE U
Date: 11.03.2006

G. Kurz

Name: Julio Cesar Castro Palomino Laria
Address: [Address]

By: _____
Date: _____

Assignee Name: Oryzon Genomics S.A.

Signature: *[Signature]*

Printed Name: CARLOS BUENA ARIOL

Corporate Title: C.E.O.

Date: 20 JULY 2016

ASSIGNMENT

WHEREAS I/We, the below-named inventor(s) (hereinafter referred to as Assignor(s)), of an invention entitled:

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

as disclosed and claimed in EP Application No. 11382325.6, filed October 20, 2011, EP Application No. 11382331.4, filed October 27, 2011, United States Provisional Patent Application No. 61/558,367, filed November 10, 2011, United States Provisional Patent Application No. 61/558,365, filed November 10, 2011, United States Application No. 14/352,711, filed April 18, 2014 (Confirmation No. 2828) and/or PCT International Application No. PCT/EP2012/070898, filed October 22, 2012 and;

WHEREAS, Oryzon Genomics S.A., a corporation of Spain whose post office address is C/Sant Ferran 74, 08940 Cornellà de Llobregat, Barcelona, Spain (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I/We, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my/our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and I/We hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY covenant that I/We have the full right to convey the interest assigned by this Assignment, and I/We have not executed and will not execute any agreement in conflict with this Assignment;

AND, I/WE HEREBY further covenant and agree that I/We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

AND, I/WE HEREBY authorize and request the attorneys empowered in the Power of Attorney in this application, to insert the filing date and application number of the above-referenced application(s) when known.

IN TESTIMONY WHEREOF, I/We have hereunto set our hands.

Name: Alberto Ortega Muñoz
Address: [Address]
By: _____
Date: _____

Name: Matthew Colin Thor Pyfe
Address: [Address]
By: _____
Date: _____

Name: Marc Martinell Pedemonte
Address: [Address]
By: _____
Date: _____

Name: Maria de los Angeles Estiarte Martinez
Address: [Address]
By: _____
Date: _____

Name: Nuria Valls Vidal
Address: [Address]
By: _____
Date: _____

Name: Guido Kurz
Address: [Address]
By: _____
Date: _____

Name: Julio Cesar Castro Palomino Laria
Address: [Address] ERNST WACH 37
08307 MA-ARO SPAIN
By: _____
Date: 11 July 2016

Assignee Name: Oryzen Genomics S.A.
Signature: [Signature]
Printed Name: CARLOS BUELA MORA
Corporate Title: C.E.O.
Date: 10 July 2016